Delveinsight

FEBRUARY 23, 2021

The company plans to use the capital to expand its pipeline of protein-based vaccines and biologic cancer therapies utilizing its innovative and proprietary Trimer-Tag technology platform. M LightDeck for SARS-CoV-2 antigen test; Libtayo for first-line advanced NSCLC subset appeared first on DelveInsight Business Research.

In-Vitro 52

In-Vitro Vaccination Vaccine Licensing 52

Delveinsight

FEBRUARY 25, 2021

The startup spun out of Georgia Tech in 2018 and is based on James Dahlman’s research, a professor in the university’s department of biomedical engineering and school of medicine. GuideTx will aid Beam in developing LNP-based medicines. Overall, this could result in a 26% overall reduction in all five-year cancer deaths.

DNA 52

DNA In-Vivo Genetics Medicine 52

XTalks

AUGUST 23, 2021

This is not a debate on approval,” said Stacie Weninger, PhD, president of the F-Prime Biomedical Research Initiative, in a focused topic session on the impact of drug approval on future clinical trials held on Tuesday July 27. Now that [aducanumab] is approved, how will this affect clinical trials going forward?”.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Drugs 52

Rethinking Clinical Trials

FEBRUARY 2, 2023

Russell, MD Assistant Professor, Department of Medicine Co-Director, Program in Medical ICU Research Division of Pulmonary, Allergy & Critical Care Medicine Assistant Medical Director, Birmingham Veterans Affairs Medical Center MICU University of Alabama at Birmingham Heersink School of Medicine Matthew W. Russell, MD; Matthew W.

Trials 130

Trials Clinical Trials Clinical Trials Medicine 130

Drug Discovery World

OCTOBER 28, 2022

Over the last seven days we’ve seen discoveries that could lead to new treatments for Covid-19, pancreatic cancer and Epstein-Barr virus, as well as the launch of the UK’s largest health research programme and the innovative application of a Nobel prize-winning chemistry technique. . This week’s top stories: .

Drugs 52

Drugs Antibody Protein RNA 52

Drug Discovery World

NOVEMBER 13, 2023

Thereafter, the following presentations will take place: Melody Shahsavarian, PhD, Digital Biologics Platform, Large Molecules Research, Sanofi, on: ‘Enhancing antibody discovery with generative AI’. Ali Madani, PhD, Founder and CEO, Profluent Bio, on: ‘Protein engineering with large language models’.

Protein 59

Protein Antibody Engineer Scientist 59

Drug Discovery World

NOVEMBER 9, 2023

Novel platforms This session will begin with chariperson’s remarks from Lars Linden, PhD, Vice President, Head, Biologics Research, Bayer HealthCare, which will be followed by a keynote presentation by Agnieszka Kielczewska, PhD, Director, Research, Antibody Discovery and Screening, Biologics Discovery, Amgen.

Engineer 52

Engineer Antibody Protein In-Vivo 52

Drug Discovery World

FEBRUARY 9, 2023

Basic research and new technologies are uncovering insights every day that build on our understanding of human biology. I believe this is where the future of drug research and development hinges. It also carries a much higher price tag for failure. On top of that, pharmaceutical development is extremely complex in itself.

Drugs 52

Drugs Development Big Data Scientist 52